Patient Voice Needed In Outcomes-Based Contracts, PhRMA Exec Says
PhRMA President and CEO Stephen Ubl says patient preferences can be among metrics in outcomes-based arrangements between biopharma and payers; experimentation needed before US government gets involved in value-based pricing.
You may also be interested in...
Amgen has negotiated 75 value-based contracts – agreements that SVP Josh Ofman sees as one area where biopharma and payer views are aligned. However, tension between the two sides remains high in pricing and reimbursement negotiations when it comes to rebates and other issues.
Novartis CEO Jimenez suggests Trump Administration may help remove regulatory barriers to US outcome-based contracting between manufacturers and payers; Duke Margolis Center for Health Policy plans policy initiative to promote value-based purchasing for drugs, medical devices and gene therapy.
Draft guidance provides clarity on what health care economic information firms can provide to payors, formulary committees and similar entities.